Follicular lymphoma is the second most frequent type of non-Hodgkin's lymphoma in adults. The basic molecular defect consists of the t(14;18)(q32;q21) translocation, juxtaposing the B-cell lymphoma protein 2 gene BCL2 to the immunoglobulin heavy chain locus IGH@, and leading to the antiapoptotic BCL2 protein overproduction. Variations in the t(14;18) are rare and can be classified into two categories: (i) simple variants, involving chromosomes 18 and 2, or 22, in which the fusion partner of BCL2 is the light-chain IGK@ or IGL@; (ii) complex variant translocations occurring among chromosomes 14, 18 and other chromosomes. We report a follicular lymphoma case showing BCL2 overexpression, detected by immunohistochemistry and real-time quantitative PCR, consequently to the formation of a novel fusion gene between the 5 0 of the lymphoid nuclear transcriptional activator gene AFF3 at 2q11.2, and the 3 0 of BCL2. This case shows evidence, for the first time, of BCL2 overexpression consequently to the fusion of BCL2 to a non-IG partner locus.
Follicular lymphoma (FL) is the second most frequent type of non-Hodgkin's lymphoma in adults (de Jong, 2005) . The t(14;18)(q32;q21) translocation juxtaposes the B-cell lymphoma protein 2 gene (BCL2), at 18q21, to the immunoglobulin heavy chain locus (IGH@) at 14q32. This rearrangement leads to the overproduction of the antiapoptotic BCL2 protein, the basic molecular defect in FL.
Variations in the t(14;18) are rare and can be classified into two categories: (i) simple variants, involving chromosome 18 and either chromosome 2 or 22, in which the fusion partner of BCL2 is the light-chain IGK@ (2p11.2) or IGL@ (22q11.2); (ii) complex variant translocations, involving chromosomes 14, 18 and one or two other chromosomes (Bentley et al., 2005) . Such variants can be considered as biologic equivalents of the t(14;18) and, therefore, more than 90% of indolent FLs express high levels of BCL2 protein (de Jong, 2005) .
Here we describe a FL case showing BCL2 overexpression, detected by immunohistochemistry and realtime quantitative PCR. This case is the result of the fusion of the 3 0 end of BCL2 with the 5 0 of AFF3 (AF4/ FMR2 family member 3 isoform 1, also known as LAF4) at 2q11.2. The chimeric gene was investigated by RT-PCR and fluorescent in situ hybridization analyses.
A 65-year-old female patient was referred to our hospital because of persistent submandibular and multiple cervical lymphadenopathy. The patient did not complain of fatigue, night sweats or significant weight loss. Laboratory findings showed elevated lactate dehydrogenase and hypergammaglobulinemia. Other biochemical values were in the normal range. A total body computerized axial tomographic scan showed enlargement of multiple submandibular, cervical, axillary and mediastinal lymph nodes. Submandibular lymph node biopsy was performed. Immunophenotyping showed positivity for CD10 and CD20. No evidence of lymphoma involvement was found in the bone marrow. On the basis of clinical, radiological, histological and immunological findings, FL stage II-A, grade 1, FLIPI score 3, was diagnosed. The patient received six cycles of rituximab, cyclophosphamide, vincristine and prednisone (R-CVP). Staging after polychemotherapy showed complete remission.
Classical cytogenetic analysis, performed on the patient's tumor cells, revealed a karyotype 47,XX,t(2;18)(q11;q21), þ 11,i(12)(q10) [8] (Figure 1a and data not shown) that was confirmed by multicolor-fluorescent in situ hybridization (Figure 1a and data not shown). Fluorescent in situ hybridization experiments, using appropriate bacterial artificial chromosome clones, revealed that the breakpoints were encompassed by the clones 004, 203, 010) RT-PCR with an AFF3 forward primer, specific for exon 1 of the transcript in form 1 (accession number: NM_002285), and a BCL2 reverse primer within the coding sequence of exon 2 of the transcript variant a (accession number: NM_000633), yielded a single band
of 393 bp ( Figure 1c ). The sequencing of the RT-PCR product revealed the occurrence of a 5 0 AFF3/3 0 BCL2 fusion transcript, in which the whole AFF3 exon 1 was fused to the entire exon 2 of BCL2 (Figures 1d and e) . The micro-homology of one nucleotide (C) occurred at the fusion junction (Figures 1d and e) . The fusion breakpoint mapped before the start of AFF3 coding sequence (AFF3 exon 2) and preserved the BCL2 ATG initiation codon, which begins at nt 87 of BCL2 exon 2 (NM_000633) (Figure 1e ). RT-PCR for the reciprocal BCL2/AFF3 fusion product, using BCL2 exon 1 forward and AFF3 exon 2 reverse primers, yielded negative results (data not shown). Immunohistochemical analysis, using a specific BCL2 antibody, showed the nuclear overexpression of the BCL2 protein in the neoplastic follicular cells (Figure 2b ).
The expression level of BCL2 and AFF3 was determined by real-time quantitative PCR, using proper primer combinations for BCL2 and AFF3 (Figures 1f  and g ). This analysis revealed that the BCL2 transcript showed comparable expression levels in our patient with respect to the IGH@/BCL2-positive FL cases (Figure 1f ). In addition, there was no statistically significant mis-expression of the AFF3 transcripts in the case with the t(2;18) rearrangement versus the other three FLs without the translocation (Figure 1g) .
The overall data reported here demonstrate a novel chromosomal rearrangement in FL, that is, a t(2;18)(q11.2;p21.33) translocation, leading to the overexpression of BCL2. To the best of our knowledge, this is the first case in which BCL2 fuses with a gene other than Ig loci. Mahmoodi et al. (2004) described a novel t(16;18)(p13;q21.3) translocation in a BCL2-positive FL case, but they did not identify the candidate partner gene at 16p13.
The mechanism responsible for the transcriptional deregulation of an oncogene through its juxtaposition to an ectopic promoter is known as 'promoter swapping.' It has been reported in several tumors (pleomorphic adenoma of the salivary glands, lipoblastoma, aneurysmal bone cyst, teratoma). Similarly, in a case of primary splenic FL we have recently documented the upregulation of SOX5, one of the Sry (sex determining region Y)-box (SOX) genes. After the juxtaposition of SOX5 coding sequence to the P2RY8 (G-protein coupled purinergic receptor P2Y8) promoter sequence, A novel fusion 5 0 AFF3/3 0 BCL2 in follicular lymphoma L Impera et al it was highly active in lymph nodes and in lymph (Storlazzi et al., 2007) . The AFF3 promoter is reported to be highly expressed in lymphoid tissues (Hiwatari et al., 2003) . Rearrangements of the BCL2 gene are recurrent in B-cell tumors. In t(14;18) cases, the breakpoints are mapped within specific regions located at the 3 0 end of the gene (MBR, mcr, icr, 3 0 BCL2, 5 0 mcr) outside its coding region (Weinberg et al., 2007) . Conversely, simple variant translocations with IGL loci showed breakpoints clustering at the 5 0 end of the gene, that is, from 378 to 2312 bp upstream of the BCL2 translational initiation site (Yonetani et al., 2001) . This case showed a BCL2 breakpoint within the first intron, exactly at the same location as one FL case (case no. 61) with 5 0 -BCL2/IGLk reported in Yonetani et al. (2001) . The partner AFF3 gene encodes a lymphoid nuclear protein of 1227 amino acids with transactivation potential and is thought to have a role in early lymphoid development (Hiwatari et al., 2003) . The AFF3 is a member of a family of proteins including AFF1 (4q21.3-22.1, also known as AF4), AFF2 (Xq28, alias FMR2) and AFF4 (5q31.1, alias AF5q31), which have various similarities: size of transcripts, protein size of approximately 1300 amino acids and nuclear localization of the proteins. AFF1 and AFF4 were also found to be involved in B-cell acute lymphoblastic leukemia (ALL), as fusion partners of the MLL gene. Similarly, AFF3 has been implicated in tumorigenesis, as it was reported to be the 3 0 fusion partner of MLL (5) and RUNX1 (Chinen et al., 2008) in pediatric ALL, respectively, with B-ALL and T-ALL phenotype. In both chimeras, the breakpoint disrupting AFF3 was located within the region homologous to the transactivation domain of AFF1 and AFF4 (exons 5-7), leading to the retention of this oncogenic domain in all the AFF3 fusion proteins (Hiwatari et al., 2003; Chinen et al., 2008) . In this case, the AFF3 breakpoint was located within the 5 0 UTR region, that is, outside its coding region. It is conceivable that the AFF3 promoter is potentially able to activate the expression of BCL2, which is usually over-represented in IGs/BCL2-positive FL cases.
In conclusion, the FL case we reported shows overexpression of BCL2 resulting from its fusion with a non-IG partner. Identification of AFF3 as the partner gene was greatly facilitated by the accurate molecular cytogenetic analysis performed by appropriate bacterial artificial chromosome clones.
